Tempus Ai, Inc. · NASDAQ:TEM
Tempus Ai — ESMO Congress 2025
12 slides from Tempus Ai's conference presentation, October 2025
Slide 1: LAG-3 expression patterns and immunotherapy response in metastatic RCC
Lymphocyte activation gene-3 expression patterns and immunotherapy response in metastatic renal cell carcinoma Rana R. McKay1, Adam J. Dugan2, Unnati Jariwala2, Karyn Ronski2, Jacob Mercer2, Eddy Saad3, Jad El Masri3, Marc Machaalani3, Mustafa Jamal Saleh3, Cody Rose4, Sabina Signoretti2, David Brau
Slide 2: Declarations of Interest
Declarations of Interest • Consulting/advisor with Ambrx, Arcus, AstraZeneca, Aveo, Bayer, Blue Earth Diagnostics, Bristol- Myers Squibb, Calithera, Caris, Daiichi Sankyo, Dendreon, Exelixis, Johnson & Johnson, Lilly, Merck, Myovant, Neomorph, Nimbus, Novartis, Pfizer, Sanofi, SeaGen, Sorrento Thera
Slide 3: Background
Background Immunotherapy combinations are the new frontline treatment in RCC Outcomes to treatment are heterogenous A wide range of biomarkers have been investigated in RCC, but none are used clinically LAG-3 is an inhibitor receptor on T-cells that suppresses T-cell activation and promotes exhausti
Slide 4: Methods
Checkpoint Gene Expression Methods -CLTA-4, TIM-3, TIGIT -PD-L1, PD-1, PD-2 Immunotherapy Markers De-identified DNA-NGS (xT) -Tumor Mutation burden and RNA-NGS (xR) data -Microsatellite Instability Objective Response Rate# from patients with RCC within -PD-L1 IHC Status (22C3 Tempus multimodal datab
Slide 5: Baseline Characteristics
Baseline Characteristics Variable Overall (n=566) Q1 (n=142) Q2 (n=141) Q3 (n=141) Q4 (n=142) P-value Median age, years 61 61 61 61 61 0.571 Male 409 (72%) 98 (69%) 109 (77%) 96 (68%) 106 (75%) 0.244 Non-White Race 89 (21%) 22 (21%) 27 (27%) 20 (17%) 20 (20%) 0.352 Hispanic 65 (21%) 19 (23%) 11 (14%
Slide 6: Checkpoint Gene Expression and IO Markers
Checkpoint Gene Expression and IO Markers Positive Correlation Between Checkpoint Gene RNA No Association Between IO Markers and 7 Expression and LAG-3 RNA Expression Quartiles LAG-3 RNA Expression Quartiles p=0.380 12% (Pearson coefficient displayed) 11.0% Gene Expression (Log2(TMP+1)) 6 10% 8.8% 5
Slide 7: Associations with Immune Cell Fraction
Associations with Immune Cell Fraction Increased LAG-3 RNA p=0.007 Positive Association Between Immune Cell Fraction 16 15 expression suggests tumor and LAG-3 RNA Expression Quartiles 14 profile that is inflamed yet 14 13 exhausted 12 12 Percent of Cells in Sample p=<0.001 10 9 p=<0.001 p=<0.001 8 p
Slide 8: Associations with Somatic Alterations
Associations with Somatic Alterations 80% Positive Association Between Increased BAP1 and NF2 Alterations 70% in Tumors with Increased LAG-3 RNA Expression 60% • BAP1 loss-of-function mutations associated with enhanced tumor immunogenicity • Increased neoantigen presentation, 50% • Upregulated MHC c
Slide 9: LAG-3 Expression Associated with ORR
LAG-3 Expression Associated with ORR Increased LAG-3 RNA Expression Associated with Increased 60% Responses and Decreased Progressive Disease (p=0.034) 51% 50% 47% 45% 42% 40% 37% 29% 30% 30% 28% 28% 22% 20% 18% 19% 10% 3% 0% 0% 1% 0% Complete Response Partial Response Stable Disease Progressive Dis
Slide 10: No Association Between LAG-3 Expression and OS
No Association Between LAG-3 Expression and OS LAG-3 Quartile Median Overall HR 95% CI P-Value (n=339) Survival Q1 25.7 (18.9, 45.0) - - - Q2 29.8 (24.9, 41.8 0.85 0.53, 1.36 0.5 Q3 29.0 (24.6, NA) 0.75 0.48, 1.20 0.2 Q4 35.0 (27.0, NA) 0.74 0.46, 1.18 0.2 rwOS=Real world overall survival; HR=Hazard
Slide 11: Conclusions
Conclusions Tumors with higher LAG-3 expression demonstrated a decreased proportion of liver metastases. LAG-3 RNA expression positively correlated with other checkpoint genes, suggesting severe T cell dysfunction and adaptive immune resistance. Tumors with high LAG3 expression exhibited a complex i
Slide 12: European Society for Medical Oncology (ESMO)
European Society for Medical Oncology (ESMO) Via Ginevra 4, CH-6900 Lugano T. +41 (0)91 973 19 00 esmo@esmo.org esmo.org